These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Vascular damage and lack of angiogenesis in systemic sclerosis skin. Konttinen YT; Mackiewicz Z; Ruuttila P; Ceponis A; Sukura A; Povilenaite D; Hukkanen M; Virtanen I Clin Rheumatol; 2003 Sep; 22(3):196-202. PubMed ID: 14505210 [TBL] [Abstract][Full Text] [Related]
4. Platelet activation, endothelial cell dysfunction in the absence of anticardiolipin antibodies in systemic sclerosis. Lima J; Fonollosa V; Fernández-Cortijo J; Ordi J; Cuenca R; Khamashta MA; Vilardell M; Simeón CP; Picó M J Rheumatol; 1991 Dec; 18(12):1833-6. PubMed ID: 1839040 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. Blann AD; Illingworth K; Jayson MI J Rheumatol; 1993 Aug; 20(8):1325-30. PubMed ID: 8230013 [TBL] [Abstract][Full Text] [Related]
6. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235 [TBL] [Abstract][Full Text] [Related]
7. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis. Gardinali M; Pozzi MR; Bernareggi M; Montani N; Allevi E; Catena L; Cugno M; Bottasso B; Stabilini R J Rheumatol; 2001 Apr; 28(4):786-94. PubMed ID: 11327251 [TBL] [Abstract][Full Text] [Related]
8. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Cerinic MM; Valentini G; Sorano GG; D'Angelo S; Cuomo G; Fenu L; Generini S; Cinotti S; Morfini M; Pignone A; Guiducci S; Del Rosso A; Kalfin R; Das D; Marongiu F Semin Arthritis Rheum; 2003 Apr; 32(5):285-95. PubMed ID: 12701039 [TBL] [Abstract][Full Text] [Related]
9. Inverse relation between plasma concentration of von Willebrand factor and CrEDTA clearance in systemic sclerosis. Scheja A; Eskilsson J; Akesson A; Wollheim FA J Rheumatol; 1994 Apr; 21(4):639-42. PubMed ID: 8035386 [TBL] [Abstract][Full Text] [Related]
10. Comparison of coagulation factor XIII content and concentration in cryoprecipitate and fresh-frozen plasma. Caudill JS; Nichols WL; Plumhoff EA; Schulte SL; Winters JL; Gastineau DA; Rodriguez V Transfusion; 2009 Apr; 49(4):765-70. PubMed ID: 19192257 [TBL] [Abstract][Full Text] [Related]
11. Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Del Papa N; Colombo G; Fracchiolla N; Moronetti LM; Ingegnoli F; Maglione W; Comina DP; Vitali C; Fantini F; Cortelezzi A Arthritis Rheum; 2004 Apr; 50(4):1296-304. PubMed ID: 15077314 [TBL] [Abstract][Full Text] [Related]
12. Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. Macko RF; Gelber AC; Young BA; Lowitt MH; White B; Wigley FM; Goldblum SE J Rheumatol; 2002 Dec; 29(12):2565-70. PubMed ID: 12465153 [TBL] [Abstract][Full Text] [Related]
13. Inter-relationships of indices of endothelial damage/dysfunction [circulating endothelial cells, von Willebrand factor and flow-mediated dilatation] to tissue factor and interleukin-6 in acute coronary syndromes. Lee KW; Blann AD; Lip GY Int J Cardiol; 2006 Aug; 111(2):302-8. PubMed ID: 16324758 [TBL] [Abstract][Full Text] [Related]
14. Endothelial cell activation and blood coagulation in critically ill patients with lung injury. Wenzel C; Kofler J; Locker GJ; Laczika K; Quehenberger P; Frass M; Knöbl P Wien Klin Wochenschr; 2002 Oct; 114(19-20):853-8. PubMed ID: 12503477 [TBL] [Abstract][Full Text] [Related]
16. Factor XIII and Endothelial Dysfunction in Patients with Systemic Sclerosis. Alesci S; Wahle M; Himsel A; Miesbach W Hamostaseologie; 2023 Dec; 43(6):411-417. PubMed ID: 37127039 [TBL] [Abstract][Full Text] [Related]
17. Coagulation factor XIII in scleroderma. Jullien D; Souillet AL; Faure M; Claudy A Eur J Dermatol; 1998 Jun; 8(4):231-4. PubMed ID: 9649677 [TBL] [Abstract][Full Text] [Related]
18. Von Willebrand factor antigen levels in Behçet disease. Beyan E; Sadikoğlu B; Ertuğrul E; Beyan C Am J Hematol; 2005 May; 79(1):70-2. PubMed ID: 15849757 [TBL] [Abstract][Full Text] [Related]
19. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Apras S; Ertenli I; Ozbalkan Z; Kiraz S; Ozturk MA; Haznedaroglu IC; Cobankara V; Pay S; Calguneri M Arthritis Rheum; 2003 Aug; 48(8):2256-61. PubMed ID: 12905480 [TBL] [Abstract][Full Text] [Related]
20. Comprehensive investigation of disease-specific short peptides in sera from patients with systemic sclerosis: complement C3f-des-arginine, detected predominantly in systemic sclerosis sera, enhances proliferation of vascular endothelial cells. Xiang Y; Matsui T; Matsuo K; Shimada K; Tohma S; Nakamura H; Masuko K; Yudoh K; Nishioka K; Kato T Arthritis Rheum; 2007 Jun; 56(6):2018-30. PubMed ID: 17530642 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]